• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

Development and characterization Theophylline and budesonide, a hydrophilic and lipophilic medication, are co-encapsulated

    Deepa. N, Prithivirajan. E, Elaveyini. E, Gnanisha. M, Thamizharasi. S, Tamil Selvan.S, Suryanarayanan. P, Kishan Kumar. S.B, Tamilanban. D, Sandhiya .V, Swarnamugi. G, Ramya. P, Sherlin Kirubha. T

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 10587-10591

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Drug-encapsulated biodegradable polymeric nanoparticles are suitable for therapeutic molecule delivery to the lungs. The current study sought to encapsulate a hydrophilic drug (theophylline) and a lipophilic drug (budesonide) in poly(lactic acid) (PLA) nanoparticles for pulmonary drug delivery. PLA nanoparticles were created using a double emulsification solvent diffusion method and were evaluated for particle size, zeta potential, drug loading, in vitro drug release, interactions with an airway epithelial cell line (16HBE14o-), and in vitro deposition properties upon nebulization. The spherically-shaped mono- and co-encapsulated PLA nanoparticles had particle sizes ranging from 190 to 400 nm and a zeta potential ranging from 10 to 16mV. Sustained drug release from nanoparticles into a mixture of simulated lung fluid and methanol (1:1) was observed over 24 hours when measured using Franz diffusion cells and when assessed for permeability using 16HBE14o-cells. After 24 hours of exposure to drug-encapsulated nanoparticles at nebulized concentrations, there was no significant reduction in cell viability (p > 0.05). Nebulization of co-encapsulated nanoparticles yielded a fine particle fraction of 75% for theophylline and 48% for budesonide, respectively. Based on these findings, it is possible to conclude that budesonide and theophylline drug-loaded PLA nanoparticles are appropriate drug delivery systems for combination therapy of asthma and COPD.
Keywords:
  • PDF (131 K)
  • XML
(2022). Development and characterization Theophylline and budesonide, a hydrophilic and lipophilic medication, are co-encapsulated. European Journal of Molecular & Clinical Medicine, 9(3), 10587-10591.
Deepa. N, Prithivirajan. E, Elaveyini. E, Gnanisha. M, Thamizharasi. S, Tamil Selvan.S, Suryanarayanan. P, Kishan Kumar. S.B, Tamilanban. D, Sandhiya .V, Swarnamugi. G, Ramya. P, Sherlin Kirubha. T. "Development and characterization Theophylline and budesonide, a hydrophilic and lipophilic medication, are co-encapsulated". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 10587-10591.
(2022). 'Development and characterization Theophylline and budesonide, a hydrophilic and lipophilic medication, are co-encapsulated', European Journal of Molecular & Clinical Medicine, 9(3), pp. 10587-10591.
Development and characterization Theophylline and budesonide, a hydrophilic and lipophilic medication, are co-encapsulated. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 10587-10591.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 31
  • PDF Download: 60
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus